<?xml version="1.0" encoding="UTF-8"?>
<p id="p0065">With the arrival of the COVID-19 epidemic in early 2020, government and industry sponsors scrambled to launch clinical trials to evaluate interventions that might favorably impact COVID-19 disease, including products already approved for use in other indications and others being newly developed [
 <xref rid="bib10" ref-type="bibr">[10]</xref>, 
 <xref rid="bib11" ref-type="bibr">[11]</xref>, 
 <xref rid="bib12" ref-type="bibr">[12]</xref>, 
 <xref rid="bib13" ref-type="bibr">[13]</xref>]. These trials have largely followed the traditional clinical trial structure, including the use of DMCs that are guided by best practices based on decades of experiences [
 <xref rid="bib4" ref-type="bibr">4</xref>]. From our initial experiences, there are some emerging challenges that DMCs will have to address to meet both ethical and scientific needs.
</p>
